Mr. Will Rascan reports

NOVA MENTIS ANNOUNCES CHANGE OF DIRECTORS

Nova Mentis Life Science Corp. has appointed Steve Loutskou to the company's board of directors, effective Feb. 23, 2024.

Mr. Loutskou, a seasoned serial entrepreneur, boasts a career spanning over 20 years, marked by numerous success stories. From the initiation of early-stage start-ups to steering them through mature commercialization phases, he has demonstrated exceptional skills in navigating the intricate landscape of financing. With two decades of experience in business management, operations and financing, he has garnered a wealth of experiences spanning various sectors of industry.

A trail-blazer in innovative ventures, Mr. Loutskou's strategic vision and financial acumen have not only accelerated start-ups to success but have also attracted substantial investment. His continued influence remains pivotal in shaping the future of business through insightful strategies and adept financial management.

Derek Ivany, chairman of the company, stated: "I have had the distinct honour of collaborating with Steve across multiple projects, notably in the triumphant revitalization of a plant-based enterprise. I eagerly anticipate joining forces with Steve again to pioneer groundbreaking strategies for Nova, aimed at elevating our business operations."

About Nova Mentis Life Science Corp.

Nova Mentis Life Science is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotechnology company to achieve orphan drug designation in both the United States and the European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS).

Nova's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs (such as autism spectrum disorder (ASD) and FXS).

We seek Safe Harbor.